<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of Rocky Mountain spotted fever</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of Rocky Mountain spotted fever</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of Rocky Mountain spotted fever</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Micah T McClain, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel J Sexton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Rocky Mountain spotted fever (RMSF) is a potentially lethal, but usually curable, tick-borne disease. RMSF occurs throughout the United States, Canada, Mexico, Central America, and in parts of South America. The etiologic agent, <em>Rickettsia rickettsii</em>, is a gram-negative, obligate intracellular bacterium that causes a wide spectrum of clinical disease ranging from mild to fulminant infection. Mortality from RMSF has declined markedly, from 2.2 percent in 2000 to 0.3 percent in 2007 and has been essentially unchanged since that time [<a href="#rid1">1,2</a>]. </p><p>The treatment of RMSF will be reviewed here. The basic biology of <em>R. rickettsii</em>, and the epidemiology, clinical manifestations, and diagnosis of RMSF are discussed separately. (See  <a class="medical medical_review" href="/d/html/7902.html" rel="external">"Biology of Rickettsia rickettsii infection"</a> and  <a class="medical medical_review" href="/d/html/7904.html" rel="external">"Clinical manifestations and diagnosis of Rocky Mountain spotted fever"</a>.)</p><p class="headingAnchor" id="H4101120159"><span class="h1">APPROACH</span><span class="headingEndMark"> — </span>We recommend empiric therapy with <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> for patients with suspected RMSF, even if the symptoms are mild. Early therapy for RMSF is critical since a delay in treatment has been associated with an increased risk of mortality. </p><p class="headingAnchor" id="H1953367993"><span class="h2">When to suspect RMSF</span><span class="headingEndMark"> — </span>A diagnosis of RMSF should be suspected in patients who are from an endemic area (or have visited one within the past 14 days) if they:</p><p class="bulletIndent1"><span class="glyph">●</span>Present in the spring and summer months with fever and at least one of the following: headache, rash, constitutional symptoms, RMSF-associated laboratory abnormalities (thrombocytopenia, elevated liver functions tests [LFTs], etc).<em> </em>(See  <a class="medical medical_review" href="/d/html/7904.html" rel="external">"Clinical manifestations and diagnosis of Rocky Mountain spotted fever", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/7904.html" rel="external">"Clinical manifestations and diagnosis of Rocky Mountain spotted fever", section on 'Laboratory findings'</a>.)</p><p></p><p class="bulletIndent1"><strong>and</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Have a known tick bite or an exposure to outdoor areas where ticks are common. (See  <a class="medical medical_review" href="/d/html/7904.html" rel="external">"Clinical manifestations and diagnosis of Rocky Mountain spotted fever", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/d/html/7904.html" rel="external">"Clinical manifestations and diagnosis of Rocky Mountain spotted fever", section on 'Vectors'</a>.) </p><p></p><p class="headingAnchor" id="H575010625"><span class="h2">Patients suspected to have RMSF</span><span class="headingEndMark"> — </span>Antimicrobial therapy should be initiated as soon as possible in all patients who are suspected to have RMSF. (See <a class="local">'When to suspect RMSF'</a> above.) </p><p>It is particularly important that empiric therapy not be delayed if RMSF is suspected in patients who are severely ill (eg, severe headache or abdominal pain) and/or those who present with possible complications associated with RMSF (eg, seizures, hypotension, noncardiogenic pulmonary edema, jaundice). (See <a class="local">'Importance of early therapy'</a> below and <a class="local">'Choice of antibiotic'</a> below.) </p><p>Most patients will require empiric therapy for RMSF based upon clinical judgment and the epidemiologic setting since RMSF can rarely be confirmed or disproved in its early phase. Clinicians should <strong>not </strong>wait for the skin rash to develop before initiating treatment. (See <a class="local">'Importance of early therapy'</a> below.)</p><p>Patients with mild disease can generally be treated safely as an outpatient. By contrast, patients with severe symptoms should be hospitalized. Additional management considerations for patients with severe disease include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric treatment for alternative diagnoses</strong> – Patients with RMSF may require empiric treatment for an alternative diagnosis while awaiting results from the initial diagnostic evaluation (see  <a class="medical medical_review" href="/d/html/7904.html" rel="external">"Clinical manifestations and diagnosis of Rocky Mountain spotted fever", section on 'Differential diagnosis'</a>). As an example, the early signs and symptoms of invasive meningococcal infection and RMSF are often difficult to distinguish. Thus, patients should receive empiric antibiotic therapy for both conditions if their symptoms are consistent with invasive meningococcal disease and RMSF. (See  <a class="medical medical_review" href="/d/html/1290.html" rel="external">"Initial therapy and prognosis of community-acquired bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/d/html/6010.html" rel="external">"Bacterial meningitis in children older than one month: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care</strong> – Severely ill patients with RMSF should undergo hemodynamic monitoring since both hypovolemia and hypervolemia can occur. The tendency to hypervolemia in this setting is related to both the frequent presence of heart failure due to myocarditis and an increase in systemic vascular permeability [<a href="#rid3">3,4</a>]. Mechanical ventilation, dialysis, transfusions, and medications to control seizures also may be needed.</p><p></p><p class="headingAnchor" id="H45432632"><span class="h2">Importance of early therapy</span><span class="headingEndMark"> — </span>Treatment should be initiated within five days of symptom onset. Early therapy for RMSF is important since a delay in treatment has been associated with an increased risk of mortality [<a href="#rid5">5-8</a>]. The importance of early therapy is illustrated in the following studies: </p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 94 patients with RMSF, those who were treated within five days of symptom onset were significantly less likely to die than those who were treated after the fifth day (6.5 versus 22.9 percent) [<a href="#rid5">5</a>]. In this study, 90 percent of patients saw a clinician during the first five days of illness; however, over half did not receive antirickettsial therapy at that time. Failure to initiate antirickettsial therapy was associated with absence of a skin rash, presentation within the first three days of illness, and presentation from August through April. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a different study, 205 cases of confirmed or probable RMSF were retrospectively reviewed [<a href="#rid8">8</a>]. Among the patients who died, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> was initiated ≥6 days after symptom onset (median seven days compared with three days in those who did not die). Late initiation of antimicrobial therapy may have been due, in part, to a delay in including RMSF in the differential diagnosis. </p><p></p><p>For some patients, a delay in therapy may result from providers being unaware of the importance of early treatment. As an example, in a study of 84 providers, 23 percent incorrectly stated that it was appropriate to wait for the development of a skin rash before initiating therapy for RMSF [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H3"><span class="h1">CHOICE OF ANTIBIOTIC</span></p><p class="headingAnchor" id="H77984725"><span class="h2">Doxycycline as preferred agent</span><span class="headingEndMark"> — </span>We recommend orally or intravenously administered <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> for the treatment of RMSF in adults and children [<a href="#rid10">10,11</a>]. For patients who experience common side effects to doxycycline (eg, nausea, diarrhea), we administer supportive treatment, such as antiemetics and antimotility agents, to help them complete the course of treatment. (See <a class="local">'Drug toxicity'</a> below and <a class="local">'Duration of treatment'</a> below.)</p><p>The use of <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> as the preferred agent is based upon in vitro data, animal studies, and over 50 years of clinical experience [<a href="#rid11">11</a>]. In addition, studies have reported a higher incidence of death with <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a> (the only alternative agent) compared with tetracyclines [<a href="#rid7">7,12</a>]. In one retrospective study that evaluated 6388 patients with RMSF from 1981 to 1998, there were 213 deaths; the case fatality rate for patients treated only with chloramphenicol was significantly greater than that for patients treated only with tetracyclines (7.7 versus 1.6; odds ratio 5.5; 95% CI, 3.9-7.7 [<a href="#rid7">7</a>]).</p><p class="headingAnchor" id="H81409777"><span class="h3">Nonpregnant adults</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> is given as 100 mg twice daily (orally or intravenously). For critically ill patients, we administer a single loading dose of 200 mg. Some providers give a loading regimen of doxycycline 200 mg intravenously every 12 hours for 72 hours since steady state serum concentrations of doxycycline are not achieved for up to 72 hours [<a href="#rid13">13</a>]. However, this theory has never been tested in vitro or in vivo.</p><p class="headingAnchor" id="H38948640"><span class="h3">Pregnant women</span><span class="headingEndMark"> — </span>We prefer <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> for the treatment of pregnant women with RMSF rather than <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a>. It should be administered as 100 mg twice daily (orally or intravenously). This approach is consistent with recommendations by the United States Centers for Disease Control and Prevention (CDC), which reflect the opinion of experts in the field [<a href="#rid14">14</a>].</p><p><a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">Chloramphenicol</a> had traditionally been the preferred treatment for most pregnant women with RMSF. Tetracyclines were generally contraindicated in pregnancy because of the risk of hepatotoxicity in the mother [<a href="#rid11">11</a>] and adverse effects on fetal bone and teeth (eg, permanent discoloration of deciduous teeth from in utero exposure in the second and third trimesters [<a href="#rid15">15</a>], incorporation into fetal long tubular bones with transient inhibition of growth [<a href="#rid16">16</a>]). However, these events are extremely rare with <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, and subsequent evidence has supported the relative safety of doxycycline compared with older tetracyclines in both pregnancy and in children [<a href="#rid17">17,18</a>]. As an example, in a systematic review, there was no correlation between the use of doxycycline and teratogenic effects during pregnancy or dental staining in children [<a href="#rid17">17</a>]. Thus, given the efficacy of doxycycline and the lack of other good alternatives, the benefits generally outweigh the risks. </p><p class="headingAnchor" id="H5"><span class="h3">Children</span><span class="headingEndMark"> — </span>The dose of <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> for children who weigh ≤45 kg is 2.2 mg/kg/dose twice per day (maximum daily dose 200 mg) [<a href="#rid11">11,19</a>]. Children who weigh &gt;45 kg should receive the adult dose. Tetracyclines can cause dental staining when administered to children younger than eight years. However, the risk of dental staining with doxycycline is minimal if a short course is administered [<a href="#rid20">20</a>], and in an observational study of 53 children who received approximately two courses of doxycycline for RMSF before they were eight years old, none developed dental staining in their permanent teeth [<a href="#rid21">21</a>]. The use of short courses of doxycycline in children of all ages is supported by the American Academy of Pediatrics [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H77984784"><span class="h2">Alternative agent</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">Chloramphenicol</a> is the only known alternative agent for the treatment of RMSF. To our knowledge, no other alternative agents have been tested in humans. Although chloramphenicol has been found to have activity against RMSF in both animal and human studies [<a href="#rid23">23-25</a>], it appears to be less effective than <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> [<a href="#rid7">7,19</a>]. (See <a class="local">'Doxycycline as preferred agent'</a> above.)</p><p><a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">Chloramphenicol</a> is typically used in the rare setting when an individual has a history of a severe adverse reaction to <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (eg, toxic epidermal necrolysis, severe hepatoxicity). The dose of chloramphenicol is 50 mg/kg per day in four divided doses (maximum 4 grams per day); dose reductions are required if used to treat neonates [<a href="#rid26">26</a>].</p><p>However, <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a> may be difficult to rapidly obtain, and therefore, may not be a feasible option given the need to initiate therapy early in the course of disease. There is a low risk (1 in 25,000 to 40,000) of fatal aplastic anemia with chloramphenicol, and as a result, systemic use is restricted in many countries. If chloramphenicol cannot be obtained, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> is the only studied treatment option. Novel tetracycline-like derivatives such as <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a>, <a class="drug drug_general" data-topicid="118878" href="/d/drug information/118878.html" rel="external">eravacycline</a>, and <a class="drug drug_general" data-topicid="119253" href="/d/drug information/119253.html" rel="external">omadacycline</a> show promising in vitro activity against rickettsial species but have not yet been studied in human infection [<a href="#rid27">27,28</a>]. For individuals with a history of an adverse reaction to doxycycline, consultation with an allergist should be obtained, if possible, to help minimize the risk of an adverse event. </p><p>In the rare case in which there is a history of IgE-mediated allergy to <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> and <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a> is unavailable or contraindicated, rapid desensitization to doxycycline has been successfully reported [<a href="#rid29">29,30</a>].</p><p class="headingAnchor" id="H25298431"><span class="h2">Drug toxicity</span></p><p class="headingAnchor" id="H3359366651"><span class="h3">Doxycycline</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> is generally well tolerated except for mild nausea and vomiting. In addition, patients should be informed about photosensitivity associated with the use of doxycycline and counseled to take appropriate protective measures (eg, hat, long-sleeved shirts, sunscreen). Given the short duration of treatment, routine laboratory monitoring is not needed. Concerns related to the use of doxycycline in pregnancy are discussed above. (See <a class="local">'Pregnant women'</a> above.)</p><p class="headingAnchor" id="H3044774660"><span class="h3">Chloramphenicol</span><span class="headingEndMark"> — </span>Systemic <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a> should be administered in an inpatient setting where close monitoring is available. A complete blood count should be obtained at baseline and repeated every two days. The drug should be discontinued if hematologic abnormalities are observed (eg, reticulocytopenia, leukopenia, thrombocytopenia, or anemia). However, irreversible bone marrow suppression may occur weeks or months after therapy has been discontinued.</p><p>If <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a> is administered during the third trimester of pregnancy, it can be associated with "Gray baby syndrome" in premature infants and newborns [<a href="#rid31">31</a>]. "Gray baby syndrome" is characterized by cyanosis, abdominal distention, vasomotor collapse (often with irregular respiration), and death. The reaction appears to be associated with serum levels ≥50 mcg/mL [<a href="#rid32">32</a>].</p><p>Although serum drug levels of <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a> are typically measured in adults and children with hepatic or renal impairment, monitoring these levels is not practical in patients with RMSF, since the duration of therapy is short and most commercial labs do not perform this type of testing. </p><p class="headingAnchor" id="H7"><span class="h1">RESPONSE TO THERAPY</span><span class="headingEndMark"> — </span>Most patients respond quickly to therapy with rapid improvement in their clinical signs and symptoms. In general, mortality associated with RMSF is uncommon if treatment is started within five days of the onset of symptoms. (See  <a class="medical medical_review" href="/d/html/7904.html" rel="external">"Clinical manifestations and diagnosis of Rocky Mountain spotted fever", section on 'Mortality'</a>.)</p><p>Patients with mild illness will typically defervesce within 48 to 72 hours. However, patients with severe illness may remain critically ill and febrile for up to five days after institution of therapy. Clinical relapse has not been described in patients appropriately treated with either <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> or <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a>. </p><p>Patients who survive the initial episode generally undergo complete recovery and cure of the rickettsial infection [<a href="#rid33">33</a>]. However, a small percentage of patients with severe RMSF develop long-term sequelae, such as peripheral neuropathy, hemiparesis, or deafness [<a href="#rid34">34</a>]. In addition, patients with severe neurological involvement after delayed treatment can rarely have persistent and even worsening evidence of neurological damage, as detected by magnetic resonance imaging, despite the use of appropriate antimicrobial therapy [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H3762467027"><span class="h1">DURATION OF TREATMENT</span><span class="headingEndMark"> — </span>Treatment should be continued for at least three days after the patient has become afebrile; most experts recommend a minimum of five to seven days of therapy. This recommendation is based upon clinical experience, as there are no controlled trials to suggest an alternative approach. </p><p class="headingAnchor" id="H9"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>There is no effective commercially available vaccine to prevent RMSF. Thus, early detection and removal of attached ticks is the best way to prevent disease transmission. Several hours of feeding are required for an infected tick to transmit <em>R. rickettsii </em>[<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/7904.html" rel="external">"Clinical manifestations and diagnosis of Rocky Mountain spotted fever", section on 'Transmission'</a>.)</p><p>Patients who report tick bites should be advised to inform their clinicians if any symptoms (eg, fever and headache) develop in the following 14 days. (See  <a class="medical medical_review" href="/d/html/7904.html" rel="external">"Clinical manifestations and diagnosis of Rocky Mountain spotted fever", section on 'Clinical manifestations'</a>.)</p><p>Education about measures to prevent tick bites and reduce tick infestations are also important, as was illustrated in a community-based prevention program that was implemented in areas of hyperendemicity of RMSF in Mexico [<a href="#rid37">37</a>]. A more detailed discussion of how to prevent tick bites is found elsewhere. (See  <a class="medical medical_review" href="/d/html/7895.html" rel="external">"Prevention of Lyme disease", section on 'Personal protection'</a>.)</p><p>Prophylactic therapy with <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> or another <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> is <strong>not </strong>recommended following tick exposure [<a href="#rid10">10,38</a>]. Only a very small percentage of ticks (less than 2 percent) in endemic areas are infected with <em>R. rickettsii </em>[<a href="#rid39">39-41</a>], and animal data do not support the use of preventive antibiotics after a tick bite [<a href="#rid42">42</a>]. </p><p class="headingAnchor" id="H2517725586"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111579.html" rel="external">"Society guideline links: Tick-borne infections (Lyme disease, ehrlichiosis, anaplasmosis, babesiosis, and Rocky Mountain spotted fever)"</a>.)</p><p class="headingAnchor" id="H28420495"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/87295.html" rel="external">"Patient education: Rocky Mountain spotted fever (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H13979187"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Rocky Mountain spotted fever (RMSF) occurs throughout the United States, Canada, Mexico, Central America, and in parts of South America. The etiologic agent, <em>Rickettsia rickettsii</em>, causes a wide spectrum of clinical disease ranging from mild to fulminant infection. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the diagnosis of RMSF is suspected, antimicrobial therapy should be initiated as soon as possible; delays in treatment of more than five days have been associated with an increased risk of mortality. Most patients will require empiric therapy based upon clinical judgment and the epidemiologic setting since RMSF can rarely be confirmed or disproved in its early phase. (See <a class="local">'When to suspect RMSF'</a> above and <a class="local">'Importance of early therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For adults and children, we recommend <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). We prefer doxycycline even for pregnant women, since there is increasing evidence of the relative safety of doxycycline in pregnancy compared with older tetracyclines. (See <a class="local">'Approach'</a> above and <a class="local">'Choice of antibiotic'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most patients respond quickly to therapy with a rapid improvement in their clinical signs and symptoms. Treatment should be continued for at least three days after the patient has become afebrile; most experts recommend a minimum of five to seven days of therapy. (See <a class="local">'Response to therapy'</a> above and <a class="local">'Duration of treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is no commercially available vaccine to prevent RMSF. However, early detection and removal of attached ticks may prevent disease transmission. (See <a class="local">'Prevention'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Openshaw JJ, Swerdlow DL, Krebs JW, et al. Rocky mountain spotted fever in the United States, 2000-2007: interpreting contemporary increases in incidence. Am J Trop Med Hyg 2010; 83:174.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Rocky Mountain Spotted Fever, Statistics and Epidemiology. http://www.cdc.gov/rmsf/stats/ (Accessed on September 12, 2017).</li><li><a class="nounderline abstract_t">Marin-Garcia J, Gooch WM 3rd, Coury DL. Cardiac manifestations of Rocky Mountain spotted fever. Pediatrics 1981; 67:358.</a></li><li><a class="nounderline abstract_t">Rydkina E, Sahni A, Baggs RB, et al. Infection of human endothelial cells with spotted Fever group rickettsiae stimulates cyclooxygenase 2 expression and release of vasoactive prostaglandins. Infect Immun 2006; 74:5067.</a></li><li><a class="nounderline abstract_t">Kirkland KB, Wilkinson WE, Sexton DJ. Therapeutic delay and mortality in cases of Rocky Mountain spotted fever. Clin Infect Dis 1995; 20:1118.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Consequences of delayed diagnosis of Rocky Mountain spotted fever in children--West Virginia, Michigan, Tennessee, and Oklahoma, May-July 2000. MMWR Morb Mortal Wkly Rep 2000; 49:885.</a></li><li><a class="nounderline abstract_t">Holman RC, Paddock CD, Curns AT, et al. Analysis of risk factors for fatal Rocky Mountain Spotted Fever: evidence for superiority of tetracyclines for therapy. J Infect Dis 2001; 184:1437.</a></li><li><a class="nounderline abstract_t">Regan JJ, Traeger MS, Humpherys D, et al. Risk factors for fatal outcome from rocky mountain spotted Fever in a highly endemic area-Arizona, 2002-2011. Clin Infect Dis 2015; 60:1659.</a></li><li><a class="nounderline abstract_t">O'Reilly M, Paddock C, Elchos B, et al. Physician knowledge of the diagnosis and management of Rocky Mountain spotted fever: Mississippi, 2002. Ann N Y Acad Sci 2003; 990:295.</a></li><li class="breakAll">American Academy of Pediatrics. Rocky Mountain Spotted Fever. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012.</li><li><a class="nounderline abstract_t">Chapman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis--United States: a practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55:1.</a></li><li><a class="nounderline abstract_t">Dalton MJ, Clarke MJ, Holman RC, et al. National surveillance for Rocky Mountain spotted fever, 1981-1992: epidemiologic summary and evaluation of risk factors for fatal outcome. Am J Trop Med Hyg 1995; 52:405.</a></li><li><a class="nounderline abstract_t">Cunha BA. Clinical features of Rocky Mountain spotted fever. Lancet Infect Dis 2008; 8:143.</a></li><li class="breakAll">Centers for Disease Control and Prevention.Rocky Mountain Spotted Fever (RMSF); Symptoms, Diagnosis, and Treatment. https://www.cdc.gov/rmsf/symptoms/index.html (Accessed on June 06, 2017).</li><li><a class="nounderline abstract_t">Vennila V, Madhu V, Rajesh R, et al. Tetracycline-induced discoloration of deciduous teeth: case series. J Int Oral Health 2014; 6:115.</a></li><li><a class="nounderline abstract_t">Cohlan SQ, Bevelander G, Tiamsic T. Growth Inhibition of Prematures Receiving Tetracycline. Am J Dis Child 1963; 105:453.</a></li><li><a class="nounderline abstract_t">Cross R, Ling C, Day NP, et al. Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation? Expert Opin Drug Saf 2016; 15:367.</a></li><li><a class="nounderline abstract_t">Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations. Paediatr Perinat Epidemiol 2009; 23:18.</a></li><li><a class="nounderline abstract_t">Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis - United States. MMWR Recomm Rep 2016; 65:1.</a></li><li><a class="nounderline abstract_t">Lochary ME, Lockhart PB, Williams WT Jr. Doxycycline and staining of permanent teeth. Pediatr Infect Dis J 1998; 17:429.</a></li><li><a class="nounderline abstract_t">Todd SR, Dahlgren FS, Traeger MS, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever. J Pediatr 2015; 166:1246.</a></li><li class="breakAll">American Academy of Pediatrics. Rocky Mountain Spotted Fever. In: Red Book: 2018 Report of the Committee on Infectious Diseases, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), 2018. p.697.</li><li><a class="nounderline abstract_t">DuPont HL, Hornick RB, Dawkins AT, et al. Rocky Mountain spotted fever: a comparative study of the active immunity induced by inactivated and viable pathogenic Rickettsia rickettsii. J Infect Dis 1973; 128:340.</a></li><li><a class="nounderline abstract_t">DuPont HL, Hornick RB, Weiss CF, et al. Evaluation of chloramphenicol acid succinate therapy of induced typhoid fever and rocky mountain spotted fever. N Engl J Med 1970; 282:53.</a></li><li><a class="nounderline abstract_t">Breitschwerdt EB, Davidson MG, Aucoin DP, et al. Efficacy of chloramphenicol, enrofloxacin, and tetracycline for treatment of experimental Rocky Mountain spotted fever in dogs. Antimicrob Agents Chemother 1991; 35:2375.</a></li><li class="breakAll">American Academy of Pediatrics (AAP). Red Book: 2012 Report of the Committee on Infectious Diseases, 29, Pickering LK, Baker CJ, Kimberlin DW, Long SS (Eds), American Academy of Pediatrics, Elk Grove, IL 2012.</li><li><a class="nounderline abstract_t">Quade BR, Ramírez-Hernández A, Blanton LS. In Vitro Susceptibility of Rickettsia Species to Eravacycline, Omadacycline, and Tigecycline. Antimicrob Agents Chemother 2021; 65:e0066521.</a></li><li><a class="nounderline abstract_t">Blanton LS, Wilson NM, Quade BR, Walker DH. Susceptibility of Rickettsia rickettsii to Tigecycline in a Cell Culture Assay and Animal Model for Rocky Mountain Spotted Fever. Am J Trop Med Hyg 2019; 101:1091.</a></li><li><a class="nounderline abstract_t">Fernando SL, Hudson BJ. Rapid desensitization to doxycycline. Ann Allergy Asthma Immunol 2013; 111:73.</a></li><li><a class="nounderline abstract_t">Stollings JL, Chadha SN, Paul AM, et al. Doxycycline desensitization for a suspected case of ehrlichiosis. J Allergy Clin Immunol Pract 2014; 2:103.</a></li><li><a class="nounderline abstract_t">Wiest DB, Cochran JB, Tecklenburg FW. Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess. J Pediatr Pharmacol Ther 2012; 17:182.</a></li><li><a class="nounderline abstract_t">Powell DA, Nahata MC. Chloramphenicol: new perspectives on an old drug. Drug Intell Clin Pharm 1982; 16:295.</a></li><li><a class="nounderline abstract_t">Mead P. Epidemiology of Lyme Disease. Infect Dis Clin North Am 2022; 36:495.</a></li><li><a class="nounderline abstract_t">Archibald LK, Sexton DJ. Long-term sequelae of Rocky Mountain spotted fever. Clin Infect Dis 1995; 20:1122.</a></li><li><a class="nounderline abstract_t">Sun LR, Huisman TA, Yeshokumar AK, Johnston MV. Ongoing Cerebral Vasculitis During Treatment of Rocky Mountain Spotted Fever. Pediatr Neurol 2015; 53:434.</a></li><li><a class="nounderline abstract_t">Hayes SF, Burgdorfer W. Reactivation of Rickettsia rickettsii in Dermacentor andersoni ticks: an ultrastructural analysis. Infect Immun 1982; 37:779.</a></li><li><a class="nounderline abstract_t">Straily A, Drexler N, Cruz-Loustaunau D, et al. Notes from the Field: Community-Based Prevention of Rocky Mountain Spotted Fever - Sonora, Mexico, 2016. MMWR Morb Mortal Wkly Rep 2016; 65:1302.</a></li><li class="breakAll">United States Centers for Disease Control and Prevention. Rocky Mountain Spotted Fever (RMSF). https://www.cdc.gov/rmsf/healthcare-providers/treatment.html (Accessed on September 18, 2019).</li><li><a class="nounderline abstract_t">Walker DH. Rocky Mountain spotted fever: a seasonal alert. Clin Infect Dis 1995; 20:1111.</a></li><li><a class="nounderline abstract_t">Pretzman C, Daugherty N, Poetter K, Ralph D. The distribution and dynamics of Rickettsia in the tick population of Ohio. Ann N Y Acad Sci 1990; 590:227.</a></li><li><a class="nounderline abstract_t">Kakumanu ML, Ponnusamy L, Sutton H, et al. Prevalence of Rickettsia Species (Rickettsiales: Rickettsiaceae) in Dermacentor variabilis Ticks (Acari: Ixodidae) in North Carolina. J Med Entomol 2018; 55:1284.</a></li><li><a class="nounderline abstract_t">Kenyon RH, Williams RG, Oster CN, Pedersen CE Jr. Prophylactic treatment of Rocky Mountain spotted fever. J Clin Microbiol 1978; 8:102.</a></li></ol></div><div id="topicVersionRevision">Topic 7912 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20595498" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Rocky mountain spotted fever in the United States, 2000-2007: interpreting contemporary increases in incidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20595498" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Rocky mountain spotted fever in the United States, 2000-2007: interpreting contemporary increases in incidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6454108" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cardiac manifestations of Rocky Mountain spotted fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16926398" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Infection of human endothelial cells with spotted Fever group rickettsiae stimulates cyclooxygenase 2 expression and release of vasoactive prostaglandins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7619985" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Therapeutic delay and mortality in cases of Rocky Mountain spotted fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11055741" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Consequences of delayed diagnosis of Rocky Mountain spotted fever in children--West Virginia, Michigan, Tennessee, and Oklahoma, May-July 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11709786" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Analysis of risk factors for fatal Rocky Mountain Spotted Fever: evidence for superiority of tetracyclines for therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25697742" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk factors for fatal outcome from rocky mountain spotted Fever in a highly endemic area-Arizona, 2002-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860642" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Physician knowledge of the diagnosis and management of Rocky Mountain spotted fever: Mississippi, 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860642" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Physician knowledge of the diagnosis and management of Rocky Mountain spotted fever: Mississippi, 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16572105" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis--United States: a practical guide for physicians and other health-care and public health professionals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7771606" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : National surveillance for Rocky Mountain spotted fever, 1981-1992: epidemiologic summary and evaluation of risk factors for fatal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18291332" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical features of Rocky Mountain spotted fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18291332" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical features of Rocky Mountain spotted fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25083046" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Tetracycline-induced discoloration of deciduous teeth: case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Growth Inhibition of Prematures Receiving Tetracycline</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26680308" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19228311" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27172113" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis - United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9613662" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Doxycycline and staining of permanent teeth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25794784" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25794784" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4199563" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Rocky Mountain spotted fever: a comparative study of the active immunity induced by inactivated and viable pathogenic Rickettsia rickettsii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4982445" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Evaluation of chloramphenicol acid succinate therapy of induced typhoid fever and rocky mountain spotted fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1666498" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Efficacy of chloramphenicol, enrofloxacin, and tetracycline for treatment of experimental Rocky Mountain spotted fever in dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1666498" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy of chloramphenicol, enrofloxacin, and tetracycline for treatment of experimental Rocky Mountain spotted fever in dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34060898" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : In Vitro Susceptibility of Rickettsia Species to Eravacycline, Omadacycline, and Tigecycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31516114" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Susceptibility of Rickettsia rickettsii to Tigecycline in a Cell Culture Assay and Animal Model for Rocky Mountain Spotted Fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23806469" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Rapid desensitization to doxycycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24565779" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Doxycycline desensitization for a suspected case of ehrlichiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23118672" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7040026" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Chloramphenicol: new perspectives on an old drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36116831" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Epidemiology of Lyme Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7619986" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Long-term sequelae of Rocky Mountain spotted fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26294045" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Ongoing Cerebral Vasculitis During Treatment of Rocky Mountain Spotted Fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6811439" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Reactivation of Rickettsia rickettsii in Dermacentor andersoni ticks: an ultrastructural analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27880753" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Notes from the Field: Community-Based Prevention of Rocky Mountain Spotted Fever - Sonora, Mexico, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27880753" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Notes from the Field: Community-Based Prevention of Rocky Mountain Spotted Fever - Sonora, Mexico, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7619984" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Rocky Mountain spotted fever: a seasonal alert.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2378449" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The distribution and dynamics of Rickettsia in the tick population of Ohio.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29771344" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prevalence of Rickettsia Species (Rickettsiales: Rickettsiaceae) in Dermacentor variabilis Ticks (Acari: Ixodidae) in North Carolina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/97307" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prophylactic treatment of Rocky Mountain spotted fever.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
